4//SEC Filing
BCIP Life Sciences Associates, LP 4
Accession 0000899243-21-029222
CIK 0001380106other
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 4:40 PM ET
Size
24.1 KB
Accession
0000899243-21-029222
Insider Transaction Report
Form 4
Transactions
- Conversion
Class A Common Stock
2021-07-19+1,334,562→ 8,334,560 total(indirect: See footnotes) - Conversion
Series B1 Preferred Stock
2021-07-19−35,000,001→ 0 total(indirect: See footnotes)→ Class A Common Stock (6,999,998 underlying) - Purchase
Class A Common Stock
2021-07-19$20.00/sh+100,000$2,000,000→ 8,434,560 total(indirect: See footnotes) - Conversion
Series C1 Preferred Stock
2021-07-19−6,672,819→ 0 total(indirect: See footnotes)→ Class A Common Stock (1,334,562 underlying) - Conversion
Class A Common Stock
2021-07-19+6,999,998→ 6,999,998 total(indirect: See footnotes)
Transactions
- Purchase
Class A Common Stock
2021-07-19$20.00/sh+100,000$2,000,000→ 8,434,560 total(indirect: See footnotes) - Conversion
Class A Common Stock
2021-07-19+1,334,562→ 8,334,560 total(indirect: See footnotes) - Conversion
Series B1 Preferred Stock
2021-07-19−35,000,001→ 0 total(indirect: See footnotes)→ Class A Common Stock (6,999,998 underlying) - Conversion
Class A Common Stock
2021-07-19+6,999,998→ 6,999,998 total(indirect: See footnotes) - Conversion
Series C1 Preferred Stock
2021-07-19−6,672,819→ 0 total(indirect: See footnotes)→ Class A Common Stock (1,334,562 underlying)
Transactions
- Conversion
Series C1 Preferred Stock
2021-07-19−6,672,819→ 0 total(indirect: See footnotes)→ Class A Common Stock (1,334,562 underlying) - Conversion
Class A Common Stock
2021-07-19+6,999,998→ 6,999,998 total(indirect: See footnotes) - Conversion
Class A Common Stock
2021-07-19+1,334,562→ 8,334,560 total(indirect: See footnotes) - Purchase
Class A Common Stock
2021-07-19$20.00/sh+100,000$2,000,000→ 8,434,560 total(indirect: See footnotes) - Conversion
Series B1 Preferred Stock
2021-07-19−35,000,001→ 0 total(indirect: See footnotes)→ Class A Common Stock (6,999,998 underlying)
BCIP Life Sciences Associates, LP
10% Owner
Transactions
- Conversion
Class A Common Stock
2021-07-19+1,334,562→ 8,334,560 total(indirect: See footnotes) - Conversion
Series B1 Preferred Stock
2021-07-19−35,000,001→ 0 total(indirect: See footnotes)→ Class A Common Stock (6,999,998 underlying) - Conversion
Series C1 Preferred Stock
2021-07-19−6,672,819→ 0 total(indirect: See footnotes)→ Class A Common Stock (1,334,562 underlying) - Conversion
Class A Common Stock
2021-07-19+6,999,998→ 6,999,998 total(indirect: See footnotes) - Purchase
Class A Common Stock
2021-07-19$20.00/sh+100,000$2,000,000→ 8,434,560 total(indirect: See footnotes)
Koppel Adam
10% Owner
Transactions
- Purchase
Class A Common Stock
2021-07-19$20.00/sh+100,000$2,000,000→ 8,434,560 total(indirect: See footnotes) - Conversion
Series B1 Preferred Stock
2021-07-19−35,000,001→ 0 total(indirect: See footnotes)→ Class A Common Stock (6,999,998 underlying) - Conversion
Series C1 Preferred Stock
2021-07-19−6,672,819→ 0 total(indirect: See footnotes)→ Class A Common Stock (1,334,562 underlying) - Conversion
Class A Common Stock
2021-07-19+6,999,998→ 6,999,998 total(indirect: See footnotes) - Conversion
Class A Common Stock
2021-07-19+1,334,562→ 8,334,560 total(indirect: See footnotes)
Schwartz Jeffrey Lawrence
Director10% Owner
Transactions
- Purchase
Class A Common Stock
2021-07-19$20.00/sh+100,000$2,000,000→ 8,434,560 total(indirect: See footnotes) - Conversion
Class A Common Stock
2021-07-19+6,999,998→ 6,999,998 total(indirect: See footnotes) - Conversion
Series C1 Preferred Stock
2021-07-19−6,672,819→ 0 total(indirect: See footnotes)→ Class A Common Stock (1,334,562 underlying) - Conversion
Class A Common Stock
2021-07-19+1,334,562→ 8,334,560 total(indirect: See footnotes) - Conversion
Series B1 Preferred Stock
2021-07-19−35,000,001→ 0 total(indirect: See footnotes)→ Class A Common Stock (6,999,998 underlying)
Footnotes (7)
- [F1]Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F2]Represents 31,750,072 shares of the Issuer's Series B1 Preferred Stock held by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 3,249,929 shares of the Issuer's Series B1 Preferred Stock held by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities"), which were automatically converted into 6,350,013 and 649,985 shares of the Issuer's Class A Common Stock, respectively, immediately prior to the closing of the Issuer's initial public offering.
- [F3]Represents 6,053,214 shares of the Issuer's Series C1 Preferred Stock held by BCLS and 619,605 shares of the Issuer's Series C1 Preferred Stock held by BCIPLS, which were automatically converted into 1,210,642 and 123,920 shares of the Issuer's Class A Common stock, respectively, immediately prior to the closing of the Issuer's initial public offering.
- [F4]Represents 90,714 and 9,286 shares of the Issuer's Class A Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering.
- [F5]Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- [F6]Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.
- [F7]Jeffrey Schwartz is a director of the Issuer.
Documents
Issuer
RAPID MICRO BIOSYSTEMS, INC.
CIK 0001380106
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001702921
Filing Metadata
- Form type
- 4
- Filed
- Jul 20, 8:00 PM ET
- Accepted
- Jul 21, 4:40 PM ET
- Size
- 24.1 KB